Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)

CUSIP: 29337E102

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
58,923,077
Total 13F shares
39,000,634
Share change
-77,951
Total reported value
$539,791,932
Price per share
$13.84
Number of holders
61
Value change
-$652,659
Number of buys
29
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q4 2023

As of 31 Dec 2023, Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 39,000,634 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, 5AM Venture Management, LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, CITADEL ADVISORS LLC, Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., and VANGUARD GROUP INC. This page lists 61 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.